8,518 Shares in Natera, Inc. $NTRA Bought by Private Advisory Group LLC

Private Advisory Group LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 8,518 shares of the medical research company’s stock, valued at approximately $3,521,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of NTRA. Trust Co. of Vermont purchased a new position in Natera during the 2nd quarter valued at about $26,000. Elevation Wealth Partners LLC bought a new stake in Natera during the second quarter valued at approximately $30,000. Continuum Advisory LLC purchased a new stake in shares of Natera in the 2nd quarter worth $33,000. Rakuten Securities Inc. bought a new position in shares of Natera in the second quarter worth about $35,000. Finally, Burkett Financial Services LLC purchased a new position in Natera during the third quarter valued at approximately $57,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Leerink Partners set a $330.00 price target on Natera in a report on Friday, August 7th. Canaccord Genuity Group upped their price objective on Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. TD Cowen increased their target price on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Morgan Stanley upped their price target on Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Citigroup upped their price target on Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Insider Buying and Selling

In other news, insider John Fesko sold 302 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $400.01, for a total transaction of $120,803.02. Following the transaction, the insider directly owned 195,276 shares of the company’s stock, valued at $78,112,352.76. This represents a 0.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 470 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $391.49, for a total transaction of $184,000.30. Following the completion of the transaction, the chief financial officer owned 45,779 shares of the company’s stock, valued at $17,922,020.71. This represents a 1.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 47,056 shares of company stock valued at $17,760,989 over the last 90 days. Insiders own 5.05% of the company’s stock.

Natera Trading Up 1.0%

Shares of NASDAQ NTRA opened at $322.94 on Friday. The company has a 50-day moving average of $379.87 and a 200 day moving average of $271.22. The stock has a market cap of $46.83 billion, a PE ratio of -283.28 and a beta of 1.55. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. The company had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. During the same quarter last year, the firm posted ($0.64) earnings per share. The firm’s quarterly revenue was up 34.1% on a year-over-year basis. On average, sell-side analysts forecast that Natera, Inc. will post -1.25 EPS for the current fiscal year.

About Natera

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.